Agnelli C, Bouza E, del Carmen Martínez-Jiménez M, et al. - Between 2012–2017, a retrospective study was performed to include all adults diagnosed with candidemia the tertiary university hospital who had at least 2 serum β-D-glucan (BDG) determinations throughout the episode of fungemia (Fungitell Assay; positive cut-off ≥ 80pg/mL). Researchers compared epidemiology and clinical outcomes between patients with all negative vs any positive BDG tests. A total of 148 individuals were included in the study. In comparison with the comparative group, candidemic patients with persistently negative BDG tests present a better prognosis, probably due to a lower systemic fungal burden. The data reveal that the appropriate usage of persistently negative BDG outcomes could be an aid to individualize therapeutic management in the near future.